Eli Lilly also has a small molecule ( Muvalaplin) in the pipeline (phase 2, I think) as well:
Novartis has a phase 3 study of their drug (Pelacarsen) set to be completed in May 2025:
https://clinicaltrials.gov/study/NCT04023552
Additionally, Amgen has a drug (Olpasiran) in phase 3 set to be completed in Dec 2026:
https://clinicaltrials.gov/study/NCT05581303
These phase 3 studies are being done in patients that have elevated Lp(a) and heart disease. It is unclear if lowering Lp(a) will have a profound impact on lowering the number of events in these patient populations. The Novartis trial started in late 2019 and has been going for four years. They have not stopped the trial, so there likely have not been issues with severe adverse reactions. That said, it likely is not producing a profound benefit relative to the placebo group.
Hopefully they end up working well and the lowering of Lp(a) does have a robust clinical effect. I personally have elevated levels. There’s not a lot of emphasis on testing for this in the United States. Some of this could be due to there not being any proven treatment to address the issue.
There does appear to be a relatively strong relationship between elevated Lp(a) and coronary artery disease and heart valve calcification. Hypertension alone but also in the context of elevated Lp(a) is definitely not a good thing to have. There was a study published in in late 2022 that examined the effects of elevated Lp(a) in the MESA study population:
Association of Lp(a) (Lipoprotein[a]) and Hypertension in Primary Prevention of Cardiovascular Disease: The MESA
summary:Elevated Lp(a) Can Increase Cardiovascular Risk in People with High Blood Pressure
Upon analysis, results indicated there was no increase in risk for cardiovascular disease events for those with elevated Lp(a) and no hypertension relative to their counterparts without elevated Lp(a) and no hypertension in fully adjusted models (HR, 1.09 [95% CI, 0.79-1.50]). In contrast, when compared to those without elevated Lp(a) and no hypertension, results indicated those a statistically significant increase in cardiovascular event risk was observed among those without elevated Lp(a) and with hypertension (HR, 1.66 [95% CI, 1.39-1.98]) as well as those with elevated Lp(a) and with hypertension (HR, 2.07 [95% CI, 1.63-2.62]). Further analysis suggested those with elevated Lp(a) and with hypertension had an increased risk of cardiovascular disease events (HR, 1.24 [95% CI, 1.01-.153]) relative to their counterparts with hypertension but without elevated Lp(a).
“We found that the overwhelming amount of cardiovascular risk in this diverse population appears to be due to hypertension,” Rikhi said. “Additionally, individuals with hypertension had even higher cardiovascular risk when lipoprotein(a) was elevated. The fact that lipoprotein(a) appears to modify the relationship between hypertension and cardiovascular disease is interesting, and suggests important interactions or relationships for hypertension, lipoprotein(a) and cardiovascular disease, and more research is needed.”
edit: Here is a calculator that may provide some insight in to how elevated Lp(a) can increase the risk of heart attack or stroke:
https://www.lpaclinicalguidance.com/
Novel AI algorithm could help personalise the prevention of cardiovascular disease